3+ day, 23+ hour ago   (293+ words) Sept 10 (Reuters) – Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug ​after rodent findings, sending its shares down more than ‌15% in early trading. • The U....

5+ day, 16+ hour ago   (317+ words) Sept 8 (Reuters) – Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis’ treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns ​about the prospects of similar therapies for the tough-to-treat ‌rare disease. Dyne’s stock led declines…...

6+ day, 1+ hour ago   (257+ words) Sept 8 (Reuters) – Bristol Myers Squibb said on Tuesday its experimental cell therapy showed a high overall response rate in a mid-stage trial, ​in patients with a hard-to-treat form of ‌blood cancer. The study evaluated the therapy, called arlocabtagene autoleucel, or…...

1+ week, 34+ min ago   (191+ words) Sept 7 (Reuters) – Novo Nordisk said on Monday it had halted two additional trials of its ​experimental cardiovascular drug ziltivekimab, further ‌denting the Danish drugmaker’s efforts to diversify beyond its blockbuster obesity and diabetes franchise. In July, Novo said ziltivekimab failed…...

1+ week, 2+ day ago   (464+ words) By Christy Santhosh and Bhanvi Satija Sept 4 (Reuters) – Novartis said on Friday its experimental drug pelacarsen did not cut the risk of major heart attacks and strokes in patients with a genetic risk factor in a late-stage trial, marking a…...

1+ week, 6+ day ago   (461+ words) LONDON, Sept 1 (Reuters) – Swiss drugmaker Novartis said on Tuesday its oral drug remibrutinib outperformed an older treatment in reducing relapses in patients with a form of multiple sclerosis, boosting hopes the medicine could become a blockbuster product. The trial results…...

1+ week, 6+ day ago   (207+ words) Sept 1 (Reuters) – AstraZeneca and China’s Hutchmed said on Tuesday that a late-stage trial of a combination of their ​cancer drugs Tagrisso and Orpathys ‌significantly improved progression-free survival when given early for a type of lung cancer. Cancer therapies make up…...

1+ week, 6+ day ago   (320+ words) Sept 1 (Reuters) – Novartis said on Tuesday it paused eight clinical trials of an experimental cell therapy, called rap-cel, targeting autoimmune and neurological disorders in late August, after ​three patients died. The halt was implemented on August 24 ‌after Novartis was notified…...

2+ week, 2+ day ago   (313+ words) By Kamal Choudhury and Mariam Sunny Aug 28 (Reuters) – The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat ​a rare blood cancer, the health regulator said on ‌Friday. The approval of…...

2+ week, 6+ day ago   (328+ words) By Kunal Das and Padmanabhan Ananthan Aug 24 (Reuters) – The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson’s drug to treat a rare blood disorder, ​the company said on Monday. The approval makes Imaavy the ‌first…...